. . "216503-57-0"@en . . . . "Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia."@en . . . . "* 0.18 L/kg"@en . . "approved"@en . . "investigational"@en . . "Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells."@en . . . . . . . . . . . . . . "Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin."@en . . "# Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H: Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983 Oct;62(4):873-82. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6349718 # Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature. 1988 Mar 24;332(6162):323-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3127726 # IGMT \"Link\":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1BEY # IGMT \"Link\":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1CE1 # IGMT \"Link\":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=8005"@en . . "~288 hrs"@en . . "Alemtuzumab"@en .